Creative Biolabs, a world leader in genetic engineering and biotechnology field, has launched a new series of antibody-cytokine fusion proteins. Creative Biolabs is continuing optimizing and developing a series of functional cytokine fusion antibodies, simultaneously, a growing number of new antibody-cytokine fusion proteins.
It is widely known that cytokines play an important role in the regulation of immune responses both in physiological and pathological states and they have been evaluated in clinical trials and shown promising results in the treatment of different malignancies. The development of antibody-cytokine fusion proteins offers a means for target delivery of cytokines toward the tumor site, which has significantly improved the therapeutic index of these immunomodulatory molecules. Therefore, these immunocytokine molecules were shown to have striking anti-tumor activity and may provide a useful approach to the treatment of cancer.
Antibody-cytokine fusion proteins (ACFPs), which consist of cytokines fused to an antibody to improve antibody-targeted cancer immunotherapy. These molecules have the capacity to enhance the tumoricidal activity of the antibodies and/or activate a secondary antitumor immune response and have the properties of all components and acquire advantages compared to proteins alone. Structurally, there are two main types of ACFPs which cytokines can be alternatively fused to either whole immunoglobulin or antigen-binding fragments. Besides, differences in the composition of the fusion proteins are also due to the cytokine itself since many cytokines are composed of a single monomeric protein domain, while others are homodimeric, homotrimeric molecules or heterodimeric. Each cytokine can be fused at the amino- or carboxy-terminus of the antibody, which depends on the structure of the cytokine and antibody, and in order to conserve the biological activity of both components. Further improvements also include the fusion of different cytokines to an antibody.
“Creative Biolabs always offers a comprehensive line of high-quality antibody-cytokine fusion proteins, which turn out to have good biological activity, low or non-immunogenic and high production yield.” Commented by one of the company’s regular customers.
Creative Biolabs scientists are focusing on applying excellent science and technology to discover and develop potential new antibody-cytokine fusion proteins with the goal of becoming the first-in-class therapeutics. “We aim at providing reliable and cost-effective antibody-cytokine fusion proteins with outstanding solubility in aqueous solutions, endotoxin free and subnanomolar high affinity.” Said by chief scientist of the antibody department of Creative Biolabs.
About Creative Biolabs
Creative Biolabs is a global leading custom antibody provider. The advancement of its antibody production platforms and highly professional experts allows the company to provide efficient high throughput and super-sensitivity services, including bispecific antibody production, therapeutic antibodies and so on.
Media Contact
Company Name: Creative Biolabs
Contact Person: Bella Smith
Email: Send Email
Phone: 1-631-619-7922
Address:45-1 Ramsey Road
City: Shirley
State: New York
Country: United States
Website: https://www.creative-biolabs.com/